



JOSÉ JIMENO, MD, PHD

DR. JOSÉ JIMENO IS A MEDICAL ONCOLOGIST, WHO ALSO HOLDS A PhD IN MOLECULAR PHARMACOLOGY FROM THE UNIVERSITY OF BARCELONA. HE IS THE CHIEF MEDICAL OFFICER AT PHOSPLATIN THERAPEUTICS, A PHARMACEUTICAL COMPANY DEVELOPING PT-112, A PYROPHOSPHATE CONJUGATE CURRENTLY IN ADVANCED PHASE I CLINICAL TRIALS.

HE HAS HAD A FOCUS IN DRUG DEVELOPMENT FOR OVER TWENTY YEARS. AS VP OF CLINICAL AND SCIENTIFIC DEVELOPMENT AT PHARMAMAR, HE WAS RESPONSIBLE FOR THE INTEGRATED DEVELOPMENT OF YONDELIS®, WHICH IS APPROVED IN THE U.S., THE E.U., JAPAN, AND MORE THAN 60 OTHER COUNTRIES FOR THE TREATMENT OF OVARIAN CANCER AND SARCOMA. HE WAS ALSO INVOLVED WITH THE EARLY CLINICAL DEVELOPMENT OF APLIDINE AND IN THE DESIGN OF ITS PIVOTAL STUDY IN MULTIPLE MYELOMA. HIS PRIOR INDUSTRY ROLES ALSO INCLUDE WORK AT FARMITALIA CARLO ERBA AND AT US BIOSCIENCE, WHERE HE FOCUSED ON NOVEL COMPOUNDS (ANTHRACYCLINES, ANTI-METABOLITES, AND CYTOPROTECTORS). PRIOR TO JOINING PHOSPLATIN, DR. JIMENO WAS CO-FOUNDER AND CEO OF PANGAEA BIOTECH, A CANCER DIAGNOSTICS COMPANY FOCUSED ON PERSONALIZED MEDICINE, WHERE HE WAS INVOLVED IN THE DEVELOPMENT OF THE EGFR MUTATION DIAGNOSTIC APPROVED BY THE FDA FOR USE IN NON-SMALL CELL LUNG CANCER PATIENTS. HE HAS ALSO DONE RESEARCH ON THE MICROBIOME AS A TOOL IN CANCER THERAPY. DR. JIMENO IS AUTHOR/CO-AUTHOR OF MORE THAN 100 PAPERS IN PEER REVIEW JOURNALS ON CANCER RESEARCH.